Sugi Predict

Sugi Predict / Targets / MAPK13

MAPK13

Mitogen-activated protein kinase 13 · O15264 · MAPK13 on Sugi Atlas →

116,361 patent compounds predicted against MAPK13, 81,503 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL67984 SCHEMBL67984 0.89 19/20
SCHEMBL70674 SCHEMBL70674 0.60 19/20
SCHEMBL68380 SCHEMBL68380 0.75 18/20
SCHEMBL69565 SCHEMBL69565 0.68 18/20
SCHEMBL85099 SCHEMBL85099 0.68 18/20
SCHEMBL69086 SCHEMBL69086 0.68 18/20
SCHEMBL68502 SCHEMBL68502 0.67 18/20
SCHEMBL67380 SCHEMBL67380 0.65 18/20
SCHEMBL69184 SCHEMBL69184 0.65 18/20
SCHEMBL67900 SCHEMBL67900 0.64 18/20
Neflamapimod Neflamapimod (SCHEMBL156367) 1.00 17/20
SCHEMBL67023 SCHEMBL67023 0.73 17/20
SCHEMBL68162 SCHEMBL68162 0.71 17/20
SCHEMBL68452 SCHEMBL68452 0.70 17/20
SCHEMBL91495 SCHEMBL91495 0.66 17/20
SCHEMBL68861 SCHEMBL68861 0.64 17/20
SCHEMBL68686 SCHEMBL68686 0.62 17/20
SCHEMBL85106 SCHEMBL85106 0.61 17/20
SCHEMBL67346 SCHEMBL67346 0.60 17/20
SCHEMBL84724 SCHEMBL84724 0.60 17/20

Clinical trials — most relevant to MAPK13 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
RASopathy Biorepository nanRECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Muscle Wasting in Cancer (MWIC) nanCOMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Histiocytic Disorder Follow-up Study nanRECRUITING
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPK13 binder may also engage these)

ProteinNameSimilarity
Q9Z1B7 — 1.000 Q9Z1B7 →
Q9WTY9 — 1.000 Q9WTY9 →
Q63538 — 1.000 Q63538 →
Q3T0N5 — 1.000 Q3T0N5 →
Q9N272 — 1.000 Q9N272 →
O62618 — 1.000 O62618 →
O08911 — 1.000 O08911 →
Q9DGE1 — 0.999 Q9DGE1 →
P70618 — 0.999 P70618 →
MAPK14 Mitogen-activated protein kinase 14 0.998 landscape →
P47811 — 0.997 P47811 →
A1DES4 — 0.996 A1DES4 →
G4N374 — 0.996 G4N374 →
O02812 — 0.996 O02812 →
MAPK12 Mitogen-activated protein kinase 12 0.996 landscape →
Q4WQR3 — 0.996 Q4WQR3 →
O44408 — 0.996 O44408 →
P14681 — 0.995 P14681 →
O42376 — 0.995 O42376 →
Q9GRU1 — 0.995 Q9GRU1 →
A1CAF0 — 0.995 A1CAF0 →
A0A194WDG1 — 0.994 A0A194WDG1 →
B0Y4X4 — 0.994 B0Y4X4 →
Q17446 — 0.994 Q17446 →
Q12126 — 0.994 Q12126 →
O13352 — 0.994 O13352 →
O61443 — 0.994 O61443 →
Q9I958 — 0.993 Q9I958 →
Q4WUN7 — 0.993 Q4WUN7 →
Q9M1Z5 — 0.992 Q9M1Z5 →